Products: Cyclo-Z= Cyclo (his-pro) plus zinc, has been demonstrated to be very effective for the prevention and treatment of diabetes, obesity, and Alzheimer’s disease in various animal models and humans subjects. We obtained three different patents in the US and internationally for these disease treatments. The patent rights now belong to the US Department of Veterans Affairs (DVA) on behalf of the US government. However, DVA wants PNC to market the product. By using different combination of Cyclo-(his-pro) and zinc, three different Cyclo-Z products will be made for diabetes, obesity and Alzheimer’s disease as described in the table below.

Product Benefits

Proprietary Technologies

Several studies have suggested that diabetes is associated with defective IDE production and stimulation of IDE may improve blood sugar control. We have proven that Cyclo-Z is a potent stimulator of IDE synthesis. Furthermore, we have examined anti-diabetic activities of Cyclo-Z in five different animal models: 1) Streptozotocin-induced diabetic rats (Type 1 model); 2) ob/ob mice (Type 2 diabetes with obesity); 3) Goto-Kakizaki (G-K) rats (Type 2 diabetes without obesity); 4) aging Sprague-Dawley rats (naturally induced human insulin resistance-like or mild-Type 2 diabetes) and 5) high carbohydrate fed mice (over eating induced diabetes). We have also demonstrated anti-obesity activity that Cyclo-Z treatment significantly reduced body weight in aged obese Sprague-Dawley rats and aged diabetic G-K rats and high sucrose fed mice. Our colleagues at the VA Greater Los Angeles Healthcare System demonstrated that Cyclo-Z treatment increased IDE synthesis in human amyloid protein transgenic mice and stimulated degradation of Amyloid b protein and insulin. A 3 month pilot study of human subjects who used Pro-Z that contains various zinc metabolism stimulating agents showed significantly improved oral glucose tolerance test (OGTT) (measurement of insulin sensitivity) and decreased Hemoglobin A1c levels (measurement of average blood glucose concentration during the last three months). Urine glucose levels (indication of improved blood glucose control) were significantly decreased, while fasting blood glucose insignificantly decreased (amelioration of diabetes) . In our formal FDA standard phase 1 clinical trial, acute high dose of Cyclo-Z before breakfast in 12 healthy subjects significantly reduced blood glucose levels at 8 hours even after breakfast and lunch. In a pilot efficacy study, postprandial blood glucose levels, Hemoglobin A1c levels, and insulin requirement significantly decreased in 17 out of 18 diabetic subjects during 6 months. However, the physician noted that the remaining subject showed signs of improvement after more than 7 months of treatment.. Some subjects stopped insulin injections completely after the 6 month treatment period.

Specifically, our background studies with animal models indicate that the optimal dose of Cyclo-Z for the improvement of Three hour Average above Fasting blood Glucose Concentration (TAFGC)=accurate measurement of OGTT is 0.5 mg CHP plus 10 mg zinc/kg BW for acute treatment. The optimal daily dose for blood glucose lowering rate for 2 weeks is 0.5 mg CHP plus 10 mg zinc/L in the drinking water for genetically diabetic G-K rats, which is equivalent to 0.1mg CHP plus 2 mg zinc/Kg BW/day based on the calculation of the known amount of CHP and zinc containing water intake per day. Blood glucose levels also significantly decreased in obese ob/ob mice with the same dose (0.1 mg CHP plus 2 mg zinc /kg BW/day). Therefore, Cyclo-Z dose for the treatment of diabetes must be carefully monitored depending on the need of diabetes treatment. When insulin resistant aged S-D rats were given acute bolus of 1.0 mg CHP plus 10 mg zinc/kg BW, improved TAFGC was maintained at least one week, while the improvement of TAFGC was lost within 24 hours in G-K rats. These data suggest that the blood glucose lowering effect of Cyclo-Z treatment may be more effective and better maintained in obesity induced diabetic subjects. These pre-clinical studies with various animal models and human studies suggest that Cyclo-Z may be a very effective diabetes treatment agent.